Inhibition of Chronic and Acute Skin Inflammation by Treatment With a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor

American Journal of Pathology - United States
doi 10.2353/ajpath.2008.071074
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

The Tyrosine Kinase Inhibitor Cediranib Blocks Ligand-Induced Vascular Endothelial Growth Factor Receptor-3 Activity and Lymphangiogenesis

Cancer Research
Cancer ResearchOncology
2008English

Phase II Study of SU5416, a Small Molecule Vascular Endothelial Growth Factor Tyrosine Kinase Receptor Inhibitor, in Patients With Refractory Multiple Myeloma

Clinical Cancer Research
Cancer ResearchOncology
2004English

A Phase II Safety and Efficacy Study of the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Pazopanib in Patients With Metastatic Urothelial Cancer

Clinical Genitourinary Cancer
OncologyUrology
2013English

Brunner’s Gland Lesions in Rats Induced by a Vascular Endothelial Growth Factor Receptor Inhibitor

Toxicologic Pathology
Forensic MedicineToxicologyPathologyCell BiologyMolecular Biology
2014English

A Novel Endothelial Cell Surface Receptor Tyrosine Kinase With Extracellular Epidermal Growth Factor Homology Domains.

Molecular and Cellular Biology
Cell BiologyMolecular Biology
1992English

Increased Risk of Severe Infections in Cancer Patients Treated With Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors: A Meta-Analysis

OncoTargets and Therapy
OncologyPharmacology
2015English

Local Administration of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor May Provide a New Therapeutic Potential for the Treatment of Intractable Upper Airway Inflammation

Journal of Japan Society of Immunology & Allergology in Otolaryngology
2016English

Serum Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-1 Levels in Patients With Fibromyalgia Syndrome

Archives of Rheumatology
Rheumatology
2019English

Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors Versus Bevacizumab in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis

Molecular and Clinical Oncology
Cancer ResearchOncology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy